Inhibitor Therapeutics, Inc. (OTCMKTS:INTI) Sees Significant Increase in Short Interest

Inhibitor Therapeutics, Inc. (OTCMKTS:INTI) was the recipient of a large increase in short interest during the month of December. As of December 15th, there was short interest totalling 40,500 shares, an increase of 841.9% from the November 30th total of 4,300 shares. Based on an average daily volume of 171,400 shares, the days-to-cover ratio is presently 0.2 days.

Inhibitor Therapeutics Stock Up 19.5 %

Shares of INTI stock opened at $0.08 on Friday. The company has a 50 day moving average of $0.08 and a 200-day moving average of $0.08. Inhibitor Therapeutics has a 12-month low of $0.03 and a 12-month high of $0.14. The firm has a market cap of $13.51 million, a P/E ratio of -7.84 and a beta of -0.61.

Inhibitor Therapeutics Company Profile

Inhibitor Therapeutics, Inc, a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome.